Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes
-
- Darren K. McGuire
- Department of Internal Medicine, University of Texas Southwestern Medical Center, and Parkland Health and Hospital System, Dallas
-
- Weichung J. Shih
- Rutgers School of Public Health, Rutgers Biomedical and Health Sciences, Piscataway, New Jersey
-
- Francesco Cosentino
- Unit of Cardiology, Karolinska Institute and Karolinska University Hospital Solna, Stockholm, Sweden
-
- Bernard Charbonnel
- Department of Endocrinology, University of Nantes, Nantes, France
-
- David Z. I. Cherney
- Division of Nephrology, Department of Medicine, University Health Network, University of Toronto, Toronto, Ontario, Canada
-
- Samuel Dagogo-Jack
- Department of Medicine, University of Tennessee Health Science Center, Memphis
-
- Richard Pratley
- AdventHealth Translational Research Institute, Orlando, Florida
-
- Michelle Greenberg
- Pfizer Inc, Groton, Connecticut
-
- Shuai Wang
- Pfizer Inc, Groton, Connecticut
-
- Susan Huyck
- Merck & Co Inc, Kenilworth, New Jersey
-
- Ira Gantz
- Merck & Co Inc, Kenilworth, New Jersey
-
- Steven G. Terra
- Pfizer Inc, Andover, Massachusetts
-
- Urszula Masiukiewicz
- Pfizer Inc, Groton, Connecticut
-
- Christopher P. Cannon
- Cardiovascular Division, Brigham and Women’s Hospital, Baim Institute for Clinical Research, Harvard Medical School, Boston, Massachusetts
書誌事項
- タイトル別名
-
- A Meta-analysis
- 公開日
- 2021-02-01
- DOI
-
- 10.1001/jamacardio.2020.4511
- 公開者
- American Medical Association (AMA)
この論文をさがす
収録刊行物
-
- JAMA Cardiology
-
JAMA Cardiology 6 (2), 148-, 2021-02-01
American Medical Association (AMA)